|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
|
WO1990005144A1
(en)
|
1988-11-11 |
1990-05-17 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1992009690A2
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
AU3178993A
(en)
|
1991-11-25 |
1993-06-28 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
ATE419355T1
(de)
|
1992-02-06 |
2009-01-15 |
Novartis Vaccines & Diagnostic |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
EP1238986B1
(en)
|
1992-10-28 |
2008-06-25 |
Genentech, Inc. |
Use of Vascular endothelial cell growth factor antagonists
|
|
ES2091684T3
(es)
|
1992-11-13 |
1996-11-01 |
Idec Pharma Corp |
Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US5635388A
(en)
|
1994-04-04 |
1997-06-03 |
Genentech, Inc. |
Agonist antibodies against the flk2/flt3 receptor and uses thereof
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6066322A
(en)
|
1995-03-03 |
2000-05-23 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of immune disorders
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
ES2236634T3
(es)
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
EP2338915A3
(en)
|
1997-04-07 |
2011-10-12 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
EP0994903B1
(en)
|
1997-06-24 |
2005-05-25 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
|
JP4460155B2
(ja)
|
1997-12-05 |
2010-05-12 |
ザ・スクリプス・リサーチ・インステイチユート |
マウス抗体のヒト化
|
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
CA2369292C
(en)
|
1999-04-09 |
2010-09-21 |
Kyowa Hakko Kogyo Co. Ltd. |
Method of modulating the activity of functional immune molecules
|
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
|
US6323334B1
(en)
|
1999-09-24 |
2001-11-27 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules encoding a 103 gene product and uses therefor
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
JP2003512821A
(ja)
|
1999-10-04 |
2003-04-08 |
メディカゴ インコーポレイテッド |
外来性遺伝子の転写調節方法
|
|
WO2001029246A1
(fr)
|
1999-10-19 |
2001-04-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production d'un polypeptide
|
|
US20030180714A1
(en)
|
1999-12-15 |
2003-09-25 |
Genentech, Inc. |
Shotgun scanning
|
|
CA2395660A1
(en)
|
1999-12-29 |
2001-07-12 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
|
AU2001218871A1
(en)
|
2000-03-21 |
2001-10-03 |
Takao Arai |
Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
|
|
ATE435873T1
(de)
|
2000-03-23 |
2009-07-15 |
Genentech Inc |
Anti-c2/c2a inhibitoren zur komplement aktivierung
|
|
DK1272647T3
(en)
|
2000-04-11 |
2014-12-15 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
EA013563B1
(ru)
|
2000-10-06 |
2010-06-30 |
Киова Хакко Кирин Ко., Лтд. |
Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
DK1354034T3
(da)
|
2000-11-30 |
2008-03-25 |
Medarex Inc |
Transgene transchromosomale gnavere til fremstilling af humane antistoffer
|
|
CA2455365C
(en)
|
2001-08-03 |
2014-07-29 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
ATE430580T1
(de)
|
2001-10-25 |
2009-05-15 |
Genentech Inc |
Glycoprotein-zusammensetzungen
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
WO2003084570A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
|
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
|
CN1930288B
(zh)
|
2002-04-09 |
2012-08-08 |
协和发酵麒麟株式会社 |
基因组被修饰的细胞
|
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
|
WO2003085119A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
|
|
ES2362419T3
(es)
|
2002-04-09 |
2011-07-05 |
Kyowa Hakko Kirin Co., Ltd. |
Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
|
|
CA2488441C
(en)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
PT1572744E
(pt)
|
2002-12-16 |
2010-09-07 |
Genentech Inc |
Variantes de imunoglobulina e utilizações destas
|
|
US20070042978A1
(en)
|
2002-12-19 |
2007-02-22 |
Jean-Philippe Girard |
Nf-hev compositions and methods of use
|
|
US20050079574A1
(en)
|
2003-01-16 |
2005-04-14 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
RS20150135A1
(sr)
|
2003-05-30 |
2015-08-31 |
Genentech Inc. |
Tretman sa anti-vegf antitelima
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
|
EP1705251A4
(en)
|
2003-10-09 |
2009-10-28 |
Kyowa Hakko Kirin Co Ltd |
PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
|
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
|
NZ583292A
(en)
|
2003-11-06 |
2012-03-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
|
PL1711528T3
(pl)
|
2003-12-23 |
2012-11-30 |
Genentech Inc |
Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
|
|
NZ549040A
(en)
|
2004-02-17 |
2009-07-31 |
Schering Corp |
Use for interleukin-33 (IL33) and the IL-33 receptor complex
|
|
CA2561686C
(en)
|
2004-03-31 |
2014-12-02 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
BR122019012028B1
(pt)
|
2004-04-13 |
2023-09-26 |
F. Hoffmann-La Roche Ag |
Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
|
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
ES2551202T5
(es)
|
2005-11-04 |
2018-11-30 |
Genentech, Inc. |
Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
|
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
|
US20070237764A1
(en)
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
CN103193248A
(zh)
|
2006-02-14 |
2013-07-10 |
埃克森美孚化学专利公司 |
用于制备mfs 结构型分子筛的方法及其应用
|
|
WO2007127749A2
(en)
|
2006-04-24 |
2007-11-08 |
Critical Care Diagnostics, Inc. |
Predicting mortality and detecting severe disease
|
|
US20090305265A1
(en)
|
2006-04-27 |
2009-12-10 |
Critical Care Diagnostics, Inc. |
Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
|
|
HUE025058T2
(en)
|
2006-05-02 |
2016-01-28 |
Critical Care Diagnostics Inc |
Differential diagnosis of pulmonary and cardiovascular disease
|
|
US8147817B2
(en)
|
2006-05-04 |
2012-04-03 |
The Brigham And Women's Hospital, Inc. |
IL-33 in the treatment and diagnosis of diseases and disorders
|
|
WO2007134050A2
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
|
US8865645B2
(en)
|
2006-05-24 |
2014-10-21 |
Biogen Idec Ma Inc. |
Method of treating lung fibrosis using ST2 polypeptide
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
US7560530B1
(en)
|
2006-07-20 |
2009-07-14 |
Schering Corporation |
IL-33 receptor
|
|
ES2399075T3
(es)
|
2006-08-30 |
2013-03-25 |
Genentech, Inc. |
Anticuerpos multiespecíficos
|
|
SE532250C2
(sv)
|
2006-11-28 |
2009-11-24 |
Theravac Pharmaceuticals Ab |
Nya formuleringar av IL-33 för behandling av inflammatoriska tillstånd med en stark TH2 komponent genom vaccinering
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
IE20080331A1
(en)
|
2007-04-26 |
2009-07-08 |
Trinity College Dublin |
Products for altering cytokine activity and methods therefor
|
|
US20100260770A1
(en)
|
2007-05-18 |
2010-10-14 |
Medimmune, Llc |
Il-33 in inflammatory disease
|
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
|
JP2011500748A
(ja)
|
2007-10-26 |
2011-01-06 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
神経変性障害の治療におけるcaspaseI−依存性サイトカインの阻害剤
|
|
PT2235064E
(pt)
|
2008-01-07 |
2016-03-01 |
Amgen Inc |
Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
|
|
WO2009145810A2
(en)
|
2008-01-08 |
2009-12-03 |
University Of Massachusetts Medical School |
St2-based dengue fever diagnostic
|
|
WO2009120905A2
(en)
|
2008-03-26 |
2009-10-01 |
Cellerant Therapeutics, Inc. |
Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
|
|
PT2307454T
(pt)
|
2008-06-25 |
2017-04-26 |
Esbatech Alcon Biomed Res Unit |
Anticorpos estáveis e solúveis que inibem o vegf
|
|
US20110165063A1
(en)
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
|
PE20120586A1
(es)
|
2009-01-29 |
2012-06-17 |
Abbott Lab |
Proteinas de union a il-1
|
|
PE20160653A1
(es)
|
2009-03-05 |
2016-07-24 |
Abbvie Inc |
Proteinas de union a il-17
|
|
JP5428422B2
(ja)
|
2009-03-17 |
2014-02-26 |
ヤマハ株式会社 |
電子楽器
|
|
WO2011031600A1
(en)
|
2009-09-10 |
2011-03-17 |
Schering Corporation |
Use of il-33 antagonists to treat fibrotic disease
|
|
TW201124427A
(en)
|
2009-10-15 |
2011-07-16 |
Abbott Lab |
IL-1 binding proteins
|
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
|
DK2560683T4
(da)
|
2010-04-23 |
2022-08-29 |
Hoffmann La Roche |
Fremstilling af heteromultimeriske proteiner
|
|
EP2571532B1
(en)
|
2010-05-14 |
2017-05-03 |
Abbvie Inc. |
Il-1 binding proteins
|
|
EP2632250A1
(en)
|
2010-10-29 |
2013-09-04 |
F.Hoffmann-La Roche Ag |
Murine model of inflammation with il33 n-terminal domain deletion
|
|
KR101615474B1
(ko)
|
2010-12-16 |
2016-04-25 |
제넨테크, 인크. |
Th2 억제에 관한 진단 및 치료
|
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
|
BR112013021473A2
(pt)
*
|
2011-02-23 |
2020-08-04 |
F. Hoffmann-La Roche Ag |
anticorpos contra il33r humano e seus usos
|
|
FR2972006B1
(fr)
|
2011-02-24 |
2016-03-25 |
Centre Nat Rech Scient |
Nouveaux fragments d'il-33 superactifs et leurs utilisations
|
|
US20150306139A1
(en)
|
2011-04-21 |
2015-10-29 |
Jeffrey Ravetch |
Anti-inflammatory agents
|
|
EP2734222B1
(en)
|
2011-07-18 |
2016-10-19 |
Critical Care Diagnostics, Inc. |
Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
|
|
MX2014001019A
(es)
|
2011-07-27 |
2014-05-13 |
Glaxo Group Ltd |
Dominios variables singulares anti-vgf fusionados con dominios de fc.
|
|
PE20141562A1
(es)
|
2011-10-14 |
2014-11-12 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso
|
|
US9090694B2
(en)
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
|
CN104737023B
(zh)
|
2012-08-16 |
2017-07-28 |
重症监护诊断股份有限公司 |
预测患高血压风险的方法
|
|
WO2014062621A1
(en)
|
2012-10-15 |
2014-04-24 |
Stc.Unm |
Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
|
|
EP2916858A1
(en)
|
2012-11-08 |
2015-09-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for inducing il-2-free proliferation of gamma delta t cells
|
|
CA2894219C
(en)
|
2012-12-10 |
2020-08-11 |
Vib Vzw |
Novel interleukin-33 inhibitors
|
|
KR101780575B1
(ko)
|
2013-02-14 |
2017-09-21 |
건국대학교 산학협력단 |
신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도
|
|
WO2014128254A1
(en)
|
2013-02-22 |
2014-08-28 |
University Of Eastern Finland (Kuopion Kampus) |
Il-33 and treatment of neurodegenerative diseases
|
|
JO3532B1
(ar)
*
|
2013-03-13 |
2020-07-05 |
Regeneron Pharma |
الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
|
|
MX364591B
(es)
|
2013-03-15 |
2019-05-02 |
Regeneron Pharma |
Antagonistas de il-33 y usos de estos.
|
|
WO2014178392A1
(ja)
|
2013-05-01 |
2014-11-06 |
学校法人兵庫医科大学 |
アトピー性皮膚炎モデル動物およびその用途
|
|
WO2015042521A1
(en)
|
2013-09-20 |
2015-03-26 |
University Of Virginia Patent Foundation |
Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
|
|
CA2926025A1
(en)
|
2013-10-07 |
2015-04-16 |
The Trustees Of The University Of Pennsylvania |
Vaccines with interleukin-33 as an adjuvant
|
|
AR098155A1
(es)
|
2013-10-23 |
2016-05-04 |
Genentech Inc |
Métodos para diagnosticar y tratar trastornos eosinofílicos
|
|
WO2015077888A1
(en)
|
2013-11-28 |
2015-06-04 |
University Of Manitoba |
Idr peptide compositions and use thereof for treatment of th2-dysregulated inflammatory conditions
|
|
CA3190793A1
(en)
|
2013-12-26 |
2015-07-02 |
Mitsubishi Tanabe Pharma Corporation |
Human anti-il-33 neutralizing monoclonal antibody
|
|
AU2015204674B2
(en)
|
2014-01-10 |
2020-09-03 |
Anaptysbio, Inc. |
Antibodies directed against interleukin-33 (IL-33)
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
US20170107300A1
(en)
|
2014-03-21 |
2017-04-20 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
|
US10040859B2
(en)
|
2014-04-21 |
2018-08-07 |
The Children's Hospital Of Philadelphia |
Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody
|
|
ES2936067T3
(es)
|
2014-05-27 |
2023-03-14 |
Univ Queensland |
IL-22 para uso en el tratamiento de trastornos metabólicos
|
|
GB201413913D0
(en)
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
CN107109494B
(zh)
|
2014-11-10 |
2023-10-27 |
豪夫迈·罗氏有限公司 |
Il-33介导型疾病的治疗方法和诊断方法
|
|
CA2960297A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
US11137397B2
(en)
|
2014-11-24 |
2021-10-05 |
Albert Einstein College Of Medicine |
Peptides for blocking IL1RAP protein-protein interaction and uses thereof for treatment of disease
|
|
WO2016090250A1
(en)
|
2014-12-04 |
2016-06-09 |
The University Of North Carolina At Chapel Hill |
Compositions and methods for preventing and treating graft versus host disease
|
|
WO2016122865A1
(en)
|
2015-01-30 |
2016-08-04 |
Salk Institute For Biological Studies |
Compositions and methods for treating age-related diabetes and related disorders
|
|
CA2978449A1
(en)
|
2015-03-02 |
2016-09-09 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using an il-33 antagonist
|
|
EP3265114A4
(en)
|
2015-03-03 |
2019-11-13 |
Jefferies, Wilfred |
MODULATION OF CANCER IMMUNITY WITH BORN TYPE-2 LYMPHOID CELLS, INTERLEUKIN 33 AND / OR INTERFERON-INDUCED PROTEIN 44
|
|
CN107430117A
(zh)
|
2015-03-16 |
2017-12-01 |
豪夫迈·罗氏有限公司 |
检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
|
|
NZ736026A
(en)
|
2015-03-31 |
2023-02-24 |
Medimmune Ltd |
A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
|
|
JP7114460B2
(ja)
|
2015-06-26 |
2022-08-08 |
サノフィ・バイオテクノロジー |
モノクローナル抗IL-1RAcP抗体
|
|
CN108289930A
(zh)
|
2015-07-10 |
2018-07-17 |
香港科技大学 |
用于治疗神经退行性和神经炎性病症的方法和组合物
|
|
CL2015002153A1
(es)
|
2015-07-31 |
2016-01-29 |
Pontificia Universidad Católica De Chile |
Uso de los marcadores moleculares il-3,il33 e il-12p40 para caracterizar la severidad de infecciones respiratorias por virus respiratorio sincicial y metapneumovirus humano
|
|
MX2018004170A
(es)
|
2015-10-06 |
2018-06-06 |
Regeneron Pharma |
Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
|
|
MX2018013038A
(es)
|
2016-04-27 |
2019-03-28 |
Pfizer |
Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
|